The availability of compounded GLP-1 drugs shifted after the FDA changed their regulations in April 2025. Here’s what to know.

Several medications interact with EN, and patients should be monitored for altered clinical response or subtherapeutic drug levels. [13] The more common drug–nutrient interactions are described below.

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

Recent FDA actions offer long-awaited clarity on what constitutes a ‘minor change’ to solid oral OTC dosage forms, providing manufacturers with a clearer pathway for certain modifications while ...

Section 1. Purpose. My first term included numerous significant actions, including some of the most aggressive in recent history, to deliver lower prescription drug prices to American patients. The ...